Paratek's 2026 XHANCE Areas of Interest
Paratek supports research in multiple areas for XHANCE (fluticasone propionate), including but not exclusive to:
- Effects on Chronic Rhinosinusitis (CRS) Symptoms and/or Quality of Life
- Use in CRS patients with comorbidities
- Impact on escalation of CRS treatment (e.g., sinus surgery, use of biologics).
XHANCE Requests for Drug Product for use in IIR
The following formulations are available:
- XHANCE Exhalation Delivery System with Fluticasone Propionate (93mcg per spray)
Paratek’s 2026 XHANCE IIR Review Meeting Schedule:
- February 24, 2026 (Deadline for Submission, February 10, 2026)
- April 28, 2026 (Deadline for Submission, April 14, 2026)
- June 23, 2026 (Deadline for Submission, June 9, 2026)
- August 25, 2026 (Deadline for Submission, August 11, 2026)
- October 27, 2026 (Deadline for Submission, October 13, 2026)
- December 15, 2026 (Deadline for Submission, December 1, 2026)